Clinical Trials
7 trialsNCT05155332 2026-05-20
A Study to Test Different Doses of BI 1831169 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)
Boehringer Ingelheim
Phase 1 Suspended
NCT04058756 2025-10-07
Rollover Study for Continued Safety and Tolerability in Subjects Treated With Spartalizumab Alone or in Combination With Other Study Treatments
Novartis
Phase 1 Active not recruiting
NCT03034304 2025-07-24
A Phase I Clinical Study for Evaluating the Safety and Efficacy of MASCT-I in Patients With Advanced Solid Tumors
HRYZ Biotech Co.
Phase 1 Terminated
NCT04672434 2024-12-09
Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies
Symphogen A/S
Phase 1 Completed
NCT03523819 2024-09-19
A Study of CS1002 in Subjects with Advanced Solid Tumors
CStone Pharmaceuticals
Phase 1 Completed
NCT03874897 2024-04-30
Chimeric Antigen Receptor T Cells Targeting claudin18.2 in Solid Tumors.
Peking University
Phase 1 Completed
NCT04478461 2020-11-13
Safety, Tolerability, and Pharmacokinetics of MW11 in Patients With Advanced Solid Tumors
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 1 Unknown